In the trial a PR was observed in a c-MET amplified NSCLC, a prolonged SD with 20% tumor shrinkage in a HER2 mutant NSCLC, and prolonged SD responses in multiple other tumor types, including the almost untreatable disease, uveal melanoma. This evidence concerns the gene MET and non-small cell lung carcinoma.